Effect of Metoclopramide Versus Erythromycin on on Gastric Residual Volume
NCT ID: NCT04682691
Last Updated: 2025-01-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
50 participants
INTERVENTIONAL
2021-03-01
2024-02-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intrathecal Atropine vs IV Metoclopramide for Nausea & Vomiting During CS
NCT03932578
Effect of the Motilin Receptor Agonist, Erythromycin, on Hunger and Food Intake; Study of Role of Cholinergic Pathways
NCT02633579
Tablet Ginger Versus Tablet Doxylamine Succinate in Control of Nausea and Vomiting in Pregnancy
NCT06772974
Methylnaltrexone vs Erythromycin for Facilitating Gastric Emptying Time in Critically Ill Patients
NCT01117376
Metoclopramide on Gastric Emptying in Mechanically Ventilated Patients
NCT05641051
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group (C)
will be receive flavored water in total volume 15 ml
naturally flavored water
naturally flavored water
Group (M)
will be receive 10 ml of oral metoclopramide (10mg) + 5 ml of flavored water in total volume 15 ml
metoclopramide (10mg)
oral metoclopramide (10mg)
Group (E)
will be receive 10 ml of oral Erythromycin (400mg) + 5 ml of flavored water in total volume 15 ml
Erythromycin (400mg)
oral Erythromycin (400mg)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Erythromycin (400mg)
oral Erythromycin (400mg)
metoclopramide (10mg)
oral metoclopramide (10mg)
naturally flavored water
naturally flavored water
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Parturient scheduled for elective caesarian delivery.
* Singleton pregnancy
* Age greater than 18 years
* Having followed institutional fasting guidelines (a minimum of 2 h for clear fluids, 6 h for a light meal, and 8 h for a meal that included fried or fatty food)
Exclusion Criteria
* Deviation from fasting times
* Patients with empty stomach
* Emergency operation
* Body mass index (BMI) greater than 40 kg/m2
* American Society of Anesthesiologists (ASA) physical status class III, IV.
* Gestational diabetes mellitus
* Multiple gestations
* Patients with polyhydramnios liquor.
* Preeclampsia patients
* Chronic kidney disease patients
* Systemic diseases may cause delayed gastric emptying (eg: myopathies and myasthenia gravis).
* Patients with gastrointestinal diseases such as hiatus hernia, intestinal disease and gastro-oesophageal reflux disease and patients with history of upper gastrointestinal surgeries.
* Patients on antidepressants and monoamine oxidase inhibitors
* Use of other medications known to affect gastric motility or secretions.
* Allergy to macrolide or metoclopramide
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cairo University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Amr Samir Wahdan
Lecturer of Anesthesia, Pain management and Surgical ICU
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Amr wahdan, MD
Role: PRINCIPAL_INVESTIGATOR
Cairo university , Cairo, Egypt
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Faculty of Medicine, Cairo University.
Cairo, Egypt, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MS-381-2020
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.